▶ 調査レポート

世界の医療特殊酵素市場(~2027):製品別、ソース別、技術別、使用別、用途別、エンドユーザー別、地域別

• 英文タイトル:Healthcare Specialty Enzymes Market Research Report by Product, Source, Technique, Usage, Application, End-use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが調査・発行した産業分析レポートです。世界の医療特殊酵素市場(~2027):製品別、ソース別、技術別、使用別、用途別、エンドユーザー別、地域別 / Healthcare Specialty Enzymes Market Research Report by Product, Source, Technique, Usage, Application, End-use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 / MRC2301B053資料のイメージです。• レポートコード:MRC2301B053
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、227ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:バイオ
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥732,452 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,472,452 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社発行の当調査レポートでは、2021年に2,604.12百万ドルであった世界の医療特殊酵素市場規模が、2022年に2,820.88百万ドルに達し、2027年には4,248.77百万ドルまで年平均8.5%で成長すると予測しています。当レポートは、医療特殊酵素の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別(カーボハイドラーゼ、リパーゼ、ホスファターゼ、その他)分析、ソース別(動物、微生物、植物)分析、技術別(臨床化学技法、血液学的手法、免疫診断/免疫的測定法、微生物学的手法、分子生物学的診断法)分析、使用別(診断、研究&バイオテクノロジー)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況など、以下の構成でまとめております。なお、当書には、Advanced Enzymes Technologies Ltd.、Amano Enzymes, Inc.、Amicogen、BBI Solutions、Biocatalysts、biotechrabbit GmbH、Brain AG、Codexis、CPC Biotech、Creative Enzymes、EKF Diagnostics、F. Hoffmann-La Roche Ltd、Merck Group/KGaA、Novozymes、Sekisui Chemical Co., Ltd.などの企業情報が含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト

・世界の医療特殊酵素市場規模:製品別
- カーボハイドラーゼの市場規模
- リパーゼの市場規模
- ホスファターゼの市場規模
- その他製品の市場規模

・世界の医療特殊酵素市場規模:ソース別
- 動物由来の市場規模
- 微生物由来の市場規模
- 植物由来の市場規模

・世界の医療特殊酵素市場規模:技術別
- 臨床化学技法の市場規模
- 血液学的手法の市場規模
- 免疫診断/免疫的測定法の市場規模
- 微生物学的手法の市場規模
- 分子生物学的診断法の市場規模

・世界の医療特殊酵素市場規模:使用別
- 診断における市場規模
- 研究&バイオテクノロジーにおける市場規模

・世界の医療特殊酵素市場規模:地域別
- 南北アメリカの医療特殊酵素市場規模
アメリカの医療特殊酵素市場規模
カナダの医療特殊酵素市場規模
ブラジルの医療特殊酵素市場規模
...
- アジア太平洋の医療特殊酵素市場規模
日本の医療特殊酵素市場規模
中国の医療特殊酵素市場規模
インドの医療特殊酵素市場規模
韓国の医療特殊酵素市場規模
台湾の医療特殊酵素市場規模
...
- ヨーロッパ/中東/アフリカの医療特殊酵素市場規模
イギリスの医療特殊酵素市場規模
ドイツの医療特殊酵素市場規模
インドの医療特殊酵素市場規模
フランスの医療特殊酵素市場規模
ロシアの医療特殊酵素市場規模
...
- その他地域の医療特殊酵素市場規模

・競争状況
・企業情報

The Global Healthcare Specialty Enzymes Market size was estimated at USD 2,604.12 million in 2021 and expected to reach USD 2,820.88 million in 2022, and is projected to grow at a CAGR 8.50% to reach USD 4,248.77 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Healthcare Specialty Enzymes to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Carbohydrases, Lipases, Other Products, Phosphatases, Polymerases & Nucleases, and Proteases.

Based on Source, the market was studied across Animals, Micro-organisms, and Plants.

Based on Technique, the market was studied across Clinical Chemistry, Hematology, Immunodiagnostics/Immunoassays, Microbiology, and Molecular Diagnostics.

Based on Usage, the market was studied across Diagnosis and Research & Biotechnology.

Based on Application, the market was studied across Autoimmune Diseases, Cardiology, Diabetes, Infectious Disease, Nephrology, and Oncology.

Based on End-use, the market was studied across Hospitals, Laboratory, and Others.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Healthcare Specialty Enzymes market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Healthcare Specialty Enzymes Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Healthcare Specialty Enzymes Market, including Advanced Enzymes Technologies Ltd., Amano Enzymes, Inc., Amicogen, BBI Solutions, Biocatalysts, biotechrabbit GmbH, Brain AG, Codexis, CPC Biotech, Creative Enzymes, EKF Diagnostics, F. Hoffmann-La Roche Ltd, Merck Group/KGaA, Novozymes, Sekisui Chemical Co., Ltd., Specialty Enzymes & Probiotics, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Healthcare Specialty Enzymes Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Healthcare Specialty Enzymes Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Healthcare Specialty Enzymes Market?
4. What is the competitive strategic window for opportunities in the Global Healthcare Specialty Enzymes Market?
5. What are the technology trends and regulatory frameworks in the Global Healthcare Specialty Enzymes Market?
6. What is the market share of the leading vendors in the Global Healthcare Specialty Enzymes Market?
7. What modes and strategic moves are considered suitable for entering the Global Healthcare Specialty Enzymes Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the incidence of metabolic diseases
5.1.1.2. Incorporation of enzymes as disease markers across clinical examinations
5.1.1.3. Rising clinical in vitro diagnostics industry
5.1.1.4. Increased use of enzyme-based pharmaceutical drug formulations to treat chronic disease
5.1.2. Restraints
5.1.2.1. Lack of knowledge and technical issues
5.1.3. Opportunities
5.1.3.1. Rising demand for preventive medicine
5.1.3.2. Massive funding in the biotechnology sector and momentum increase in molecular diagnostics
5.1.4. Challenges
5.1.4.1. Legal and ethical concerns in relation to specialty enzymes
5.2. Cumulative Impact of COVID-19

6. Healthcare Specialty Enzymes Market, by Product
6.1. Introduction
6.2. Carbohydrases
6.3. Lipases
6.4. Other Products
6.5. Phosphatases
6.6. Polymerases & Nucleases
6.7. Proteases

7. Healthcare Specialty Enzymes Market, by Source
7.1. Introduction
7.2. Animals
7.3. Micro-organisms
7.4. Plants

8. Healthcare Specialty Enzymes Market, by Technique
8.1. Introduction
8.2. Clinical Chemistry
8.3. Hematology
8.4. Immunodiagnostics/Immunoassays
8.5. Microbiology
8.6. Molecular Diagnostics

9. Healthcare Specialty Enzymes Market, by Usage
9.1. Introduction
9.2. Diagnosis
9.3. Research & Biotechnology

10. Healthcare Specialty Enzymes Market, by Application
10.1. Introduction
10.2. Autoimmune Diseases
10.3. Cardiology
10.4. Diabetes
10.5. Infectious Disease
10.6. Nephrology
10.7. Oncology

11. Healthcare Specialty Enzymes Market, by End-use
11.1. Introduction
11.2. Hospitals
11.3. Laboratory
11.4. Others

12. Americas Healthcare Specialty Enzymes Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Healthcare Specialty Enzymes Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Healthcare Specialty Enzymes Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. Advanced Enzymes Technologies Ltd.
16.1.1. Business Overview
16.1.2. Key Executives
16.1.3. Product & Services
16.2. Amano Enzymes, Inc.
16.2.1. Business Overview
16.2.2. Key Executives
16.2.3. Product & Services
16.3. Amicogen
16.3.1. Business Overview
16.3.2. Key Executives
16.3.3. Product & Services
16.4. BBI Solutions
16.4.1. Business Overview
16.4.2. Key Executives
16.4.3. Product & Services
16.5. Biocatalysts
16.5.1. Business Overview
16.5.2. Key Executives
16.5.3. Product & Services
16.6. biotechrabbit GmbH
16.6.1. Business Overview
16.6.2. Key Executives
16.6.3. Product & Services
16.7. Brain AG
16.7.1. Business Overview
16.7.2. Key Executives
16.7.3. Product & Services
16.8. Codexis
16.8.1. Business Overview
16.8.2. Key Executives
16.8.3. Product & Services
16.9. CPC Biotech
16.9.1. Business Overview
16.9.2. Key Executives
16.9.3. Product & Services
16.10. Creative Enzymes
16.10.1. Business Overview
16.10.2. Key Executives
16.10.3. Product & Services
16.11. EKF Diagnostics
16.11.1. Business Overview
16.11.2. Key Executives
16.11.3. Product & Services
16.12. F. Hoffmann-La Roche Ltd
16.12.1. Business Overview
16.12.2. Key Executives
16.12.3. Product & Services
16.13. Merck Group/KGaA
16.13.1. Business Overview
16.13.2. Key Executives
16.13.3. Product & Services
16.14. Novozymes
16.14.1. Business Overview
16.14.2. Key Executives
16.14.3. Product & Services
16.15. Sekisui Chemical Co., Ltd.
16.15.1. Business Overview
16.15.2. Key Executives
16.15.3. Product & Services
16.16. Specialty Enzymes & Probiotics
16.16.1. Business Overview
16.16.2. Key Executives
16.16.3. Product & Services
16.17. Thermo Fisher Scientific, Inc.
16.17.1. Business Overview
16.17.2. Key Executives
16.17.3. Product & Services

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing